Exercise program for transthyretin heart amyloidosis
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial studies whether a structured exercise training program is safe and helpful for people with transthyretin (ATTR) cardiac amyloidosis. It may help improve fitness and daily functioning, and it may also compare groups for specific eligibility needs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ATTR heart amyloidosis (either by heart biopsy or a specific bone-scan blood flow test result).
- You have heart failure and your healthcare team has you using water pills (diuretics), plus a BNP blood test level at or above 450.
- You can walk about 4 meters (with or without a cane/walker) and manage basic daily activities on your own.
- At the time of starting the study, your heart condition is stable enough for study testing and exercise.
- You are not already doing regular moderate-to-vigorous exercise (more than 30 minutes per day, at least twice per week) for the past 6 weeks.
- You can follow the study plan and provide informed consent (and you don’t have major medical problems that block safe exercise).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a program of exercise and special nutritional supplements can help people aged 70 and older with transthyretin cardiac amyloidosis—a condition where abnormal proteins build up in the heart. It aims to see if this combination can improve heart function and quality of life.
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
This study tests a new type of heart imaging scan called [68Ga]Ga-FAPI-46 PET to help doctors see and track transthyretin cardiac amyloidosis (a disease where abnormal proteins damage the heart). The scan may help identify which patients are getting worse.
This trial studies whether ultrasound therapy can help people with amyloidosis that affects the heart. It’s aimed at improving heart-related outcomes in AL or transthyretin (ATTR) cardiac amyloidosis.
This study tests whether a supervised exercise and rehabilitation program can help people with a specific type of heart amyloidosis (ATTRwt) feel better and improve their heart function. It may be a good fit if you have stable heart failure and can safely exercise.
This study looks at whether a 5-week supervised exercise and education program can help people with a specific type of heart amyloidosis (ATTR) feel better and improve their heart function. It will check your exercise ability and heart health before and after the program.
Hear when a new Amyloid Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.